Factors Associated with Celecoxib and Rofecoxib Utilization

  title={Factors Associated with Celecoxib and Rofecoxib Utilization},
  author={Nigel S. B. Rawson and Parivash Nourjah and Stella C Grosser and David J. Graham},
  journal={Annals of Pharmacotherapy},
  pages={597 - 602}
BACKGROUND: The cyclooxygenase-2 (COX-2) selective nonsteroidal antiinflammatory drugs (NSAIDs) celecoxib and rofecoxib (before its removal) are marketed as having fewer gastrointestinal (GI)-related complications than nonselective NSAIDs. However, adverse reaction data suggest that the use of COX-2 selective NSAIDs is associated with clinically significant GI events. OBJECTIVE: To assess whether patients receiving celecoxib and rofecoxib have a greater underlying disease burden than patients… 

Tables from this paper

Use of First- and Second-Generation Cyclooxygenase-2–Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction
This study supports the hypothesis that the elevated risk of AMI is a class effect of COX-2 inhibitors, and the increase in risk appears to be dose dependent, but further data are needed to verify this observation.
Review : Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
To reduce the risk of cardiovascular complications during long-term coxib therapy, low-dose aspirin supplementation should be considered and an alternative is to use a less COX-2-selective inhibitor such as meloxicam.
Cardiovascular complications of non-steroidal anti-inflammatory drugs.
  • E. Fosslien
  • Medicine, Biology
    Annals of clinical and laboratory science
  • 2005
In conclusion, to reduce the risk of cardiovascular complications during long-term coxib therapy, low-dose aspirin supplementation should be considered and an alternative is to use a less COX-2-selective inhibitor such as meloxicam.
Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis.
There was a significant association for both selective and nonselective NSAIDs with acute renal failure, but confirmatory studies are required.
Efficacy and safety of etoricoxib in the treatment of osteoarthritis
  • A. Sebba
  • Medicine
    Expert review of clinical pharmacology
  • 2008
Large-scale studies addressing the efficacy, GI tolerability and potential for CV events with etoricoxib have now been published, and several patient types appear to benefit, including those with CV risk factors and those requiring gastroprotective agents.
Introduction — The coxib controversies
Coxibs should be set aside in a group of their own within the broader category of the NSAIDs in view of both their cardiovascular risk and unique pharmacology, and approaches for their more cautious use and marketing are presented.
An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
The typical switching behaviour of this group of women suggests that the issues leading to the discrediting of rofecoxib were not seen as a COX-2 class effect by prescribers to this high use group of consumers.
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom
The incidence of total and gastrointestinal adverse reactions was significantly lower with aceclofenac than with meloxicam or rofecoxib, thus raising doubts about the hypothetical advantage of COX-2 selective inhibitors.
Coxibs: evolution of prescription's behaviour in France
There was a positive statistical link between a high ratio of coxibs’ prescriptions and high co‐prescriptions of gastroprotective agents and a negative association with a high number of acts, a high proportion of patients with chronic disabling diseases (CDD) or ahigh number of patients between 15 and 64 years.


In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population.
COX-2 inhibitors were more commonly used than NSAIDs in patients with musculoskeletal diseases and those with prior gastrointestinal hospitalizations and adjusted odds ratios showed a 47% decrease in gastroprotective agent coprescriptions with COX- 2 inhibitors compared with NSAIDs.
Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study.
In this elderly population, long-term use of nonaspirin NSAIDs nearly halved the risk of colon cancer, consistent with previous studies that suggest that duration of use but not daily dose of NSAIDs is an important factor for chemoprevention.
Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy.
Findings suggest that opportunities exist to encourage the cost-effective prescribing of COX-2 therapy and possible methods include implementation of step therapy, academic detailing, and physician education programs, among others.
Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons.
Prescription NSAIDs represent a relatively uncommon but avoidable cause of acute renal failure in frail elderly persons and resulted in an estimated 25 excess hospitalizations associated with renal failure per 10,000 years of use.